Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis
Open Access
- 8 March 2021
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2020.00125
Abstract
To compare the efficacy and safety of physical thermal ablation (PTA), including radiofrequency ablation (RFA) and microwave ablation (MWA), combined with sorafenib and physical thermal ablation alone for the control and treatment of hepatocellular carcinoma (HCC) according to the available literature.Keywords
This publication has 33 references indexed in Scilit:
- Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular CarcinomaOncology, 2012
- Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implicationsAnnals of Oncology, 2011
- Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term resultsEuropean Journal of Surgical Oncology, 2010
- Role of sorafenib in HCC patients with compromised liver functionNature Reviews Clinical Oncology, 2009
- Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burdenJournal of Viral Hepatitis, 2009
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingMolecular Cancer Therapeutics, 2008
- Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and SunitinibThe Oncologist, 2008
- Rates and Patterns of Recurrence for Percutaneous Radiofrequency Ablation and Open Wedge Resection for Solitary Colorectal Liver MetastasisJournal of Gastrointestinal Surgery, 2007
- Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5Cancer Research, 2006